tiprankstipranks
Trending News
More News >
Geratherm Medical AG (DE:GME)
XETRA:GME
Advertisement

Geratherm Medical (GME) AI Stock Analysis

Compare
9 Followers

Top Page

DE:GME

Geratherm Medical

(XETRA:GME)

Select Model
Select Model
Select Model
Neutral 63 (OpenAI - 4o)
Rating:63Neutral
Price Target:
€4.00
▲(3.09% Upside)
Geratherm Medical's overall stock score reflects a balanced view of its financial stability, technical indicators, and attractive valuation. The strong balance sheet and improving cash flow are positive factors, while the declining revenue growth presents a challenge. Technical analysis suggests potential for a rebound, and the valuation metrics indicate the stock may be undervalued. The absence of earnings call and corporate events data limits additional insights.

Geratherm Medical (GME) vs. iShares MSCI Germany ETF (EWG)

Geratherm Medical Business Overview & Revenue Model

Company DescriptionGeratherm Medical (GME) is a global leader in the development and manufacturing of innovative medical devices, primarily focused on temperature measurement and monitoring solutions. The company operates in various sectors including healthcare, pharmaceuticals, and research, and offers a range of core products such as thermometers, blood pressure monitors, and diagnostic devices designed for both professional medical use and consumer markets.
How the Company Makes MoneyGeratherm Medical generates revenue through the sale of its medical devices and diagnostic products to hospitals, clinics, and retail pharmacies. The company has established key revenue streams through direct sales, distribution agreements, and partnerships with healthcare providers and organizations. Additionally, GME focuses on expanding its market presence in emerging economies and leverages research and development to innovate and introduce new products, thus enhancing its competitive edge and driving sales growth.

Geratherm Medical Financial Statement Overview

Summary
Geratherm Medical demonstrates a mixed financial performance. The income statement highlights profitability challenges with declining revenue growth, while the balance sheet shows financial stability with low leverage. The cash flow statement indicates improving cash generation. The company needs to address revenue growth issues while maintaining its strong balance sheet and improving cash flow conversion.
Income Statement
55
Neutral
Geratherm Medical's income statement shows a mixed performance. The TTM (Trailing-Twelve-Months) data indicates a decline in revenue growth rate by 109.5%, which is concerning. However, the company maintains a positive net profit margin of 12.27%, indicating profitability despite revenue challenges. The gross profit margin has decreased over time, reflecting potential cost management issues. Overall, the income statement reflects moderate profitability with significant revenue growth challenges.
Balance Sheet
70
Positive
The balance sheet of Geratherm Medical is relatively strong, with a low debt-to-equity ratio of 0.126 in the TTM, indicating prudent leverage management. The return on equity is modest at 8.38%, suggesting efficient use of equity to generate profits. The equity ratio remains stable, showing a solid equity base. Overall, the balance sheet reflects financial stability with low leverage and moderate returns on equity.
Cash Flow
60
Neutral
Geratherm Medical's cash flow statement shows a positive trajectory in free cash flow growth at 23.03% in the TTM, indicating improved cash generation. The operating cash flow to net income ratio is strong at 3.18, suggesting robust cash flow relative to net income. However, the free cash flow to net income ratio is slightly below 1, indicating that not all net income translates into free cash flow. Overall, the cash flow statement reflects improving cash generation with some areas for further enhancement.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue14.29M20.43M20.96M25.85M24.64M27.47M
Gross Profit5.96M12.78M6.27M6.38M16.32M17.60M
EBITDA-1.94M2.95M4.18M3.37M2.20M4.35M
Net Income1.75M705.17K1.11M1.02M122.23K2.05M
Balance Sheet
Total Assets27.53M28.54M35.72M38.38M34.56M35.99M
Cash, Cash Equivalents and Short-Term Investments9.61M9.64M7.74M10.89M6.47M10.26M
Total Debt2.62M3.28M7.23M9.29M9.32M10.40M
Total Liabilities6.95M7.71M13.11M16.15M15.93M16.07M
Stockholders Equity20.83M21.02M22.33M22.34M18.52M20.30M
Cash Flow
Free Cash Flow2.68M1.23M-212.00K-133.00K-353.00K1.14M
Operating Cash Flow2.79M1.87M1.43M2.61M917.00K3.92M
Investing Cash Flow3.89M3.82M-2.09M-767.00K3.00K-3.79M
Financing Cash Flow-2.43M-2.69M-3.09M4.35M-3.52M684.00K

Geratherm Medical Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.88
Price Trends
50DMA
3.63
Negative
100DMA
3.39
Positive
200DMA
3.32
Positive
Market Momentum
MACD
-0.06
Positive
RSI
41.08
Neutral
STOCH
11.22
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:GME, the sentiment is Negative. The current price of 3.88 is below the 20-day moving average (MA) of 4.44, above the 50-day MA of 3.63, and above the 200-day MA of 3.32, indicating a neutral trend. The MACD of -0.06 indicates Positive momentum. The RSI at 41.08 is Neutral, neither overbought nor oversold. The STOCH value of 11.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:GME.

Geratherm Medical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
€19.77M11.148.35%2.93%-23.48%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
45
Neutral
€20.86M-34.28%-0.59%24.03%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:GME
Geratherm Medical
3.88
0.70
21.97%
DE:AAQ1
aap Implantate
1.48
-0.54
-26.73%
DE:B8FK
Biofrontera
2.67
-0.13
-4.64%
DE:SBX
SynBiotic SE
2.64
-3.92
-59.76%
DE:BIG1
Bio-Gate AG
0.83
0.05
6.41%
DE:E8X
elexxion AG
0.16
-0.17
-51.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 25, 2025